Ex) Article Title, Author, Keywords
Ex) Article Title, Author, Keywords
Pharmacoepidemiology and Risk Management 2023; 15(1): 94-99
Published online March 31, 2023 https://doi.org/10.56142/perm.23.0003
Copyright © Korean Society for Pharmacoepidemiology and Risk Management.
Sun Kim1, Hyun Jee Kim2,3, Jin Yoon2,3, Jang-Ho Seo2,3, Ju-Yeun Lee1, Hye-Ryun Kang2,3,4
김선1, 김현지2,3, 윤진2,3, 서장호2,3, 이주연1, 강혜련2,3,4
Correspondence to:Hye-Ryun Kang
Departmentof Internal Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul 03080, Korea
Tel: +82-2-2072-0820
Fax: +82-2-742-3291
E-mail: helenmed@snu.ac.kr
This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Aromatase inhibitors are widely used as a treatment for postmenopausal women with hormone receptor-positive breast cancer. They are classified as type 1 steroidal or type 2 nonsteroidal agents. Letrozole and anastrozole are the most frequently used type 2 nonsteroidal inhibitors that share common structure and bind reversibly to aromatase. Both are generally well tolerated; while type A adverse reactions such as hot flashes, vaginal dryness, musculoskeletal pain, and headache can occur, drug hypersensitivity reactions are very rare. Here, we present a case of a 55 years old woman who experienced maculopapular rash to letrozole after five days administration. Her symptoms resolved after chlorpheniramine and dexamethasone injection. Then, she took a single dose of letrozole and symptoms were aggravated. Sixteen days after her initial symptom to letrozole, she switched to anastrozole. After taking anastrozole for two days, she developed urticarial rash and stopped anastrozole arbitrarily. Her symptoms resolved after discontinuing anastrozole. Patients and physicians should be aware of potential cross reactivity to both aromatase inhibitors which may be due to the common structure in the aromatase inhibitors.
KeywordsAromatase inhibitors, Drug hypersensitivity, Drug-related side effects and adverse reactions, Letrozole, Anastrozole